Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828308 | 0.88 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL22828142 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL22828137 | 0.74 | DPP7 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22828284 | 0.73 | MMP2 (0.41) | — | |
| SCHEMBL18559758 | 0.71 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL22203843 | 0.67 | PAOX (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL22828141 | 0.67 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22203854 | 0.66 | MEN1 (0.65) | GRIA1 | |
| SCHEMBL22171084 | 0.66 | PAOX (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL22171086 | 0.66 | PAOX (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | AZI2, AAAS, ZRANB2 | CHRNB2 1822/4885CHRNB4 2826/4885CHRNA3 2108/4885 |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | AZI2, AAAS, ZRANB2 | CHRNB2 1822/4885CHRNB4 2826/4885CHRNA3 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.